✦ LIBER ✦

34. Pathological and immunohistochemical prognostic factors in clinically node-negative breast cancer patients receiving adjuvant tamoxifen (BR3002 trial)

✍ Scribed by P.R. Baker; R.A. Walker; J.A. Dunn; S.M. Parnell; P.S. Stonelake; C.M. Jevons; W.M. Gillespie; P.G. Baker; L. Dodson; G.D. Oates; D.J. Ellis; M.J.R. Lee; J.M. Morrison; D. Spooner

Book ID: 113404542
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 142 KB
Volume: 4
Category: Article
ISSN: 0960-9776
DOI: 10.1016/0960-9776(95)90126-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The value of prognostic factors in selec

The value of prognostic factors in selecting node-negative breast cancer patients for adjuvant therapy

✍ Edward G. Mansour 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB

P32 Prognostic parameters in node negati

P32 Prognostic parameters in node negative breast cancer receiving adjuvant CMF: Analysis of a randomized trial with emphasis on p53 and HER 2 neu

✍ A.C. Hardy-Bessard; A. De Roquancourt; P.H. Cottu; P. De Cremoux; M. Marty; M. E 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Prognostic factors of early distant recu

Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy : Results of a retrospective analysis

✍ Marc Debled; Gaëtan MacGrogan; Véronique Brouste; Simone Mathoulin-Pelissier; Mi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## BACKGROUND Current adjuvant hormone therapy in postmenopausal women with breast cancer is debatable between upfront aromatase inhibitors (AIs) and sequential treatment with tamoxifen. A major concern is the higher rate of early recurrences observed with sequential treatment. The aut

The influence of classical prognostic fa

The influence of classical prognostic factors and adjuvant chemotherapy on disease outcome in early grade 3 node-negative, and 1–3 node-positive breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF), or untreated patients

✍ S Susnjar; I Kezic; Z Neskovic-Konstantinovic; D Gavrilovic; D Nikolic-Vukosavlj 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 319 KB